Entasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia Pacific and Global Strategic Development Collaboration for ETX2514
COLLABORATION WILL FACILITATE ENROLLMENT OF PIVOTAL GLOBAL PHASE 3 TRIAL OF ETX2514 IN COMBINATION WITH SULBACTAM FOR THE TREATMENT OF CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII INFECTIONSWALTHAM, Mass. and SHANGHAI – April 25,…